2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0381B
    Levobetaxolol hydrochloride 116209-55-3 99.31%
    Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.
    Levobetaxolol hydrochloride
  • HY-B0568R
    Deferiprone (Standard) 30652-11-0
    Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study.
    Deferiprone (Standard)
  • HY-B0660R
    Eicosapentaenoic Acid (Standard) 10417-94-4
    Eicosapentaenoic Acid (Standard) is the analytical standard of Eicosapentaenoic Acid. This product is intended for research and analytical applications. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.
    Eicosapentaenoic Acid (Standard)
  • HY-B1192R
    Estradiol benzoate (Standard) 50-50-0
    Estradiol benzoate (Standard) is the analytical standard of Estradiol benzoate. This product is intended for research and analytical applications. Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice.
    Estradiol benzoate (Standard)
  • HY-N1424R
    Glycoursodeoxycholic acid (Standard) 64480-66-6
    Glycoursodeoxycholic acid (Standard) is the analytical standard of Glycoursodeoxycholic acid. This product is intended for research and analytical applications. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid.
    Glycoursodeoxycholic acid (Standard)
  • HY-P4742A
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research.
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
  • HY-U00251
    KFM19 133058-72-7 99.44%
    KFM19 is a potent, selective Adenosine receptor (A1-receptor) antagonist, with an IC50 of 50 nM.
    KFM19
  • HY-U00281
    S16961 153874-14-7 99.85%
    S16961 is a nicotinic receptor agonist.
    S16961
  • HY-U00315
    Gidazepam 129186-29-4 98.03%
    Gidazepam is an agonist of GABA receptor channels (GABA RCs).
    Gidazepam
  • HY-113320S
    Etiocholanolone-d5 1620102-33-1 99.20%
    Etiocholanolone-d5 is the deuterium labeled Etiocholanolone. Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity. Etiocholanolone is a less potent?neurosteroid positive allosteric modulator?(PAM) of the GABAA?receptor than its?enantiomer form.
    Etiocholanolone-d5
  • HY-113524R
    N-Acetyl-L-aspartic acid (Standard) 997-55-7
    N-Acetyl-L-aspartic acid (Standard) is the analytical standard of N-Acetyl-L-aspartic acid (HY-113524). This product is intended for research and analytical applications. N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease).
    N-Acetyl-L-aspartic acid (Standard)
  • HY-124177A
    C14 Ceramide (d18:1/14:0) 123408-74-2 ≥99.0%
    C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research.
    C14 Ceramide (d18:1/14:0)
  • HY-150135B
    D-myo-Inositol 1,4,5-trisphosphate tripotassium 141611-11-2 ≥98.0%
    D-myo-Inositol 1,4,5-trisphosphate tripotassium, a second messenger, elicits Ca2+ mobilization. D-myo-Inositol 1,4,5-trisphosphate tripotassium inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2).
    D-myo-Inositol 1,4,5-trisphosphate tripotassium
  • HY-157802A
    (S)-LTGO-33 99.41%
    (S)-LTGO-33 is a small molecule inhibitor of voltage-gated sodium channel NaV1.8. (S)-LTGO-33 can be used in the treatment of pain disorders.
    (S)-LTGO-33
  • HY-17412S1
    Minocycline-d6 sulfate
    Minocycline-d6 sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6 sulfate
  • HY-P990130
    Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26)
    Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) is a mouse-derived IgG2a κ type antibody, targeting to mouse/rat CD71/TfR1. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) targets the transferrin receptor and binds to an extracellular domain for the transferrin receptor. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) can be used for the research in drug delivery, especially for drug delivery to the brain.
    Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26)
  • HY-RS16308
    mt-Co1 Mouse Pre-designed siRNA Set A

    mt-Co1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for mt-Co1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    mt-Co1 Mouse Pre-designed siRNA Set A
  • HY-W037282
    O-Desmethyl quinidine 70877-75-7 99.05%
    O-Desmethyl quinidine (Cupreidine) is an orally active metabolite of Quinine (HY-D0143). O-Desmethyl quinidine reduces frequency of cramps in rats with spinal cord injury and shows low blood toxicity.
    O-Desmethyl quinidine
  • HY-W053587
    Triazolopyridinone 6969-71-7 99.99%
    Triazolopyridinone (3-Hydroxytriazolo[4,3-a]pyridine) is an intermediate in the synthesis of the antidepressant Trazadone (HY-B0478A).
    Triazolopyridinone
  • HY-W087433
    Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate 28705-46-6 99.78%
    Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate is a potent and selective inhibitor of hMAO-B with an IC50 of 45.52 μM.
    Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate
Cat. No. Product Name / Synonyms Application Reactivity